CD274 and cancer: In recent years, PD‐1/PD‐L1 immune checkpoint inhibitors have been approved by the US Food and Drug Administration for the treatment of CRC patients.[5] Despite the great success of PD‐1/PD‐L1 blockade immunotherapy in a small subset of cancer patients, many patients do not respond and others eventually relapse due to adaptive resistance.